Moxifloxacin: the Present and the Future in the Sequential Therapy

Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(1):19-31

​ Stratchounski L.S., Veselov A.V., Kretchikov V.A.
moxifloxacin fluoroquinolones pneumonia sequential therapy
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(1):19-31

Abstract

Moxifloxacin is a new broad spectrum 8-meth-oxiquinolon with high activity against both Gram(+) and Gram(–) microorganisms as well as against anaerobes and intracellular pathogens. It is also active against microorganisms that are resistant to other classes of antimicrobials, including penicillin and macrolide-resistant pneumococci and β-lactamase-producing Haemophilus influenzae. An excellent activity against the above mentioned pathogens and good pharmacokinetic profile allows to use moxifloxacin for monotherapy of respiratory tract infections. High clinical efficacy and safety of moxifloxacin has been demonstrated in treatment with sequential therapy of community-acquired pneumonia in the controlled clinical trials. The literature review of clinical trials on sequential (IV/PO) moxifloxacin therapy in patients with community-acquired pneumonia is presented in the article. An attempt to analyse the perspectives of further moxifloxacin usage is made.

  • 1. Ricci V., Piddock L. Characterization of the QRDR ofgyrA of Bacteroides fragilis and role in fluoroquinoloneresistance. 38th ICAAC†; 1998 Sep 24–27; San Diego,USA. p. 121.
  • 2. Jones M., Staple A., Critchley I., et al. Benchmarking thein vitroactivities of moxifloxacin and comparator agentsagainst resent respiratory isolates from 377 medical cen-ters throughout the United States. Antimicrob AgentsChemother 2000;44:2645-52.
  • 3. Johnson A., Livermore D., Warner M., James D., GeorgeR. Activity of moxifloxacin against invasive and multire-sistant pneumococci from England and Wales. 39thICAAC†;1999 Sep 26–29; San Francisco, USA. p. 255.
  • 4. Milatovic D., Schmitz F., Brisse S., Verhoef J., Fluit A.In vitroactivities of sitafloxacin (DU-6859a) and sixother fluoroquinolones against 8796 clinical bacterial iso-lates. Antimicrob Agents Chemother 2000;44:1102-7.
  • 5. Buxbaum A., Straschil U., Moser C., Graninger W.,Georgopoulos A. Comparative susceptibility to penicillinand quinolones of 1385Streptococcus pneumoniaeiso-lates. J Antimicrob Chemother 1999;43 (Suppl B):13-8.
  • 6. Souli M., Weneersten C., Eliopoulos G.In vitroactivityof BAY 12-8039, a novel 8-methoxyquinolone, againstspecies representative of respiratory tract infections.37th ICAAC†, 1997: Sep 28 – Oct 1; Toronto, Canada.Poster F126.
  • 7. Blondeau J., Church D., Laskowski R., Borsos S. Compa-rative activity of moxifloxacin and other quinolonesagainst macrolide sensitive and resistantStreptococcuspyogenes. J Antimicrob Chemother 1999;44(Suppl A):131.
  • 8. Jones M., Visser M., Klootwijk M., Heisig P., Verhoef J.,Schmitz F. Comparative activities of clinafloxacin,grepafloxacin, levofloxacin, moxifloxacin, ofloxacin,sparfloxacin, and trovafloxacin and nonquinolones line-zolid, quinupristin–dalfopristin, gentamicin, and van-comycin against clinical isolates of ciprofloxacin-resis-tant and -susceptibleStaphylococcus aureusstrains.Antimicrob Agents Chemother 1999;43:421-3.
  • 9. Kretchikov V.A., Dekhnich A.V., Startchounski L.S.Comparative activity of old and new quinolones againstnosocomialStaphylococcus aureus. 12th ECCMID♦;2002 Apr 24–27; Milan, Italy. p. 261.
  • 10. Fass R.In vitroactivity of BAY 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother1997;41:1818-24.
  • 11. Woodcock J., Andrews J., Boswell F., Brenwald N., Wi-se R.In vitroactivity of BAY 12-8039, a new fluoro-quinolone. Antimicrob Agents Chemother 1997;41:101-6.
  • 12. Кречиков В., Эйдельштейн И. Активность левофлок-сацина и моксифлоксацина в отношении ципрофлок-сацин-нечувствительных нозокомиальных штаммов,продуцентовβ-лактамаз расширенного спектра(ESBL). Клин микробиол антимикроб химиотер 2001;3 Прил 1: 23.
  • 13. Duffy L., Kempf M., Crabb D., Wall W., Herrington J.Invitroactivity of moxifloxacin and six other new antimi-crobials againstMycoplasma pneumoniae. 39th ICAAC†;1999 Sep 26–29; San Francisco, USA. p. 252.
  • 14. Bebear C.M., Renaudin H., Boudjadja A., Bebear C.Invitroactivity of BAY 12-8039, a new fluoroquinoloneagainst mycoplasmas. Antimicrob Agents Chemother1998;42:703-4.
  • 15. Ullmann U., Schubert S., Krausse R. Comparativein vitroactivity of levofloxacin, other fluoroquinolones, doxycyc-line and erythromycin againstUreaplasma urealyticumandMycoplasma hominis. J Antimicrob Chemother1999;43 (Suppl C):33-6.
  • 16. Schulin T., Wennersten C., Ferraro M., Moellering R. Jr.,Eliopoulos G. Susceptibilities ofLegionellaspp. to newerantimicrobialsin vitro. Antimicrob Agents Chemother1998;42:1520-3.
  • 17. Gomez-Lus R., Adrian F., del Campo R., et al.Comparativein vitrobacteriostatic and bactericidalactivity of trovafloxacin, levofloxacin and moxifloxacinagainst clinical and environmental isolates ofLegionellaspp. Int J Antimicrob Agents 2001;18:49-54.
  • 18. Alcala L., Ruiz-Serrano M., Garcia-Arias V., Jimenez S.,Garcia de Viedma D., Bouza E.In vitroactivity of moxi-floxacin, ciprofloxacin, levofloxacin and ofloxacin againstMycobacterium tuberculosisstrains including those multi-ply-resistant to first line antituberculous drugs. 42ndICAAC; 2002 Sep 27–30; San Diego, USA. p. 155.
  • 19. Rivera-Martínez E., Pérez-González E., Garcia M.,Orrantia-Gradín R, Hernández-Oliva G, Torres-Gutierrez Rubro A. Determination of thein vitrosuscep-tibility of different strains ofM. tuberculosisto BAY12-8039 and other antituberculosis agents. 8th ICID‡;1998 May 15–18; Boston, USA. p. 173-4.
  • 20. Nord C., Edlund C. Susceptibility of anaerobic bacteriato BAY 12-8039, a new methoxyquinolone. Clin MicrobInfection 1997;3 (Suppl 2):285.
  • 21. MacGowan A., Bowker K., Holt H., Wootton M., Ree-ves D. BAY 12-8039, a new 8-methoxyquinolone: com-parativein vitroactivity with nine other antimicrobialsagainst anaerobic bacteria. J Antimicrob Chemother1997;40:503-9.
  • 22. Stass H., Kubitza D. Pharmacokinetics and elimination ofmoxifloxacin after oral and intravenous administration inman. J Antimicrob Chemother 1999;43 (Suppl B):83-90.
  • 23. Ballow C., Lettieri J., Agarwal V., Liu P., Stass H., Sul-livan J. Absolute bioavailability of moxifloxacin. ClinTher 1999;21:513-22.
  • 24. Wise R., Andrews J., Marshall G., Hartman G. Phar-macokinetics and inflammatory-fluid penetration ofmoxifloxacin following oral or intravenous administra-tion. Antimicrob Agents Chemother 1999;43:1508-10.
  • 25. Lubasch A., Keller I., Borner K., Koeppe P., Lode H. Com-parative pharmacokinetics of ciprofloxacin, gatifloxacin,grepafloxacin, levofloxacin, trovafloxacin and moxi-floxacin after single oral administration in healthy volun-teers. Antimicrob Agents Chemother 2000;44: 2600-3.
  • 26. Lettieri J., Vargas R., Agarwal V., Liu P. Effect of food onthe pharmacokinetics of a single oral dose of moxifloxacin400 mg in healthy male volunteers. Clin Pharmacokinet2001;40 (Suppl 1):19-25.
  • 27. Stass H., Kubitza D. Effects of dairy products on the oralbioavailability of moxifloxacin, a novel 8-methoxyfluoro-quinolone, in healthy volunteers. Clin Pharmacokinet2001;40 (Suppl 1):33-8.
  • 28. Sullivan J., Lettieri J., Liu P., Heller A. The influence ofage and gender on the pharmacokinetics of moxifloxacin.Clin Pharmacokinet 2001;40 (Suppl 1):11-8.
  • 29. Stass H., Halabi A., Delesen H. No dose adjustment need-ed for patients with renal impairment receiving oral BAY12-8039 (M). 38th ICAAC†; 1998 Sep 24–27; SanDiego, USA. p. 5.
  • 30. Stass H., Kubitza D. No dose adjustment is needed formoxifloxacin (MOX) in subjects suffering from hepaticimpairment (HI). Clin Microb Infection 1999;5(Suppl 3):291.
  • 31. Zhanel G., Walters M., Karlowsky J., Laing N., Hoban D.Activity of free (unbound) fluoroquinolone serum con-centrations versus multi-drug resistantStreptococcuspneumoniaeusing anin vitropharmacodynamic model.40th ICAAC†; 2000 Sep 17–20; Toronto, Canada. p. 7.
  • 32. Wright D., Brown G., Peterson M., Rotschafer J. Appli-cation of fluoroquinolones pharmacodynamics. JAntimicrob Chemother 2000;46:669-83.
  • 33. Jewesson P. Cost-effectiveness and value of an IV switch.PharmacoEconomics 1994;5 (Suppl 2):20-6.
  • 34. Jewesson P. Pharmaceutical, pharmacokinetic and otherconsidera-tions for intravenous to oral stepdown therapy.Can Infect Dis J 1995;6 (Suppl A):11-6.
  • 35. Ramirez J.A. Managing antiinfective therapy of commu-nity-acquired pneumonia in the hospital setting: focus onswitch therapy. Pharmacotherapy 2001;21:79S-82S.
  • 36. Quintiliani R., Nightingale C., Crowe H. et al. Strategicantibiotic decision-making at the formulary level. Rev InfDis 1991;13:S770-7.
  • 37. Ramirez J. Advances in antibiotic use: switch therapy.Curr Ther Res 1993;55 (A):30-4.
  • 38. Janknegt R., van der Meer J. Sequential therapy withintravenous and oral cephalosporins. J AntimicrobChemother 1994;33: 169-77.
  • 39. Страчунский Л.С., Розенсон О.Л. Ступенчатая тера-пия: новый подход к применению антибактериальныхпрепаратов. Клин фармакол тер 1997;6:20-4.
  • 40. Eisen S., Miller D., Woodward R., et al. The effect of pre-scribed daily dose frequency on patient medication com-pliance. Arch Intern Med 1990;150:1881-4.
  • 41. Nathwani D. Cost-effectiveness considerations for combination therapies. In: Antibiotic combination therapy –the role of ciprofloxacin. Cambridge Medical Publica-tions, 1997;19.
  • 42. Quintiliani R., Cooper В., Briceland L., et al. Economicimpact of streamlining antibiotic administration. Am JMed 1987;82 (Suppl 4A):391-4.
  • 43. Jewesson P. Economic impact of intravenous-to-oralantibacterial stepdown therapy. Clin Drug Invest1996;11 (Suppl 2):1-9.
  • 44. Finch R., Collins O., Kubin R. IV/PO Moxifloxacin(MXF) compared with IV/PO amoxicillin/clavulanate(AMC) +/– clarithromycin (CMP) in the treatment ofcommunity acquired pneumonia (CAP) admitted to hos-pital. 11th ECCMID♦, Istanbul, Turkey, 1–4 April,2001. p. 167.
  • 45. Choudhri S.H., Hollister A.S., Haverstock D., Wein-stein D.M., Jackson P., Church D. Safety and efficacy ofsequential (IV to PO) moxifloxacin for the treatment ofcommunity-acquired pneumonia in hospitalized patients.1st International Symposium on Resistant Gram-posi-tive Infections, San Antonio, Texas, 3–5 Dec, 2000.Poster # I-14.
  • 46. Grossman C., Choudhri S., Haverstock D., Jackson P.,Church D. Moxifloxacin intravenous-to-oral switchtherapy for severe community-acquired pneumonia.CHEST 2001, Philadelphia, Pennsylvania, 4–8 Nov,2001. Poster #187
  • 47. Larsen S., Choudhri S., Haverstock D., Jackson P.,Church D. Efficacy and safety of sequential (IV to PO)moxifloxacin for treatment of community-acquired pneu-monia due to atypical pathogens. 41st ICAAC†, Chicago,Illinois, 16–19 Dec, 2001. p. 451.
  • 48. Fogarty C., Grossman C., Williams J., Haverstock D.,Church D. Efficacy and safety of moxifloxacin vs clar-ithromycin for community-acquired pneumonia. InfectMed 1999;16:748-63.
  • 49. Hoffken G., Meyer H., Sprenger K., Verhoef L. Efficacyand safety of moxifloxacin (MXF) vs clarithromycin(Klaritro) for the treatment of community-acquiredpneumonia (CAP). J Antimicrob Chemother 1999;44(Suppl A):127.
  • 50. Chodosh S., DeAvate C., Haverstock D., Aneiro L.,Church D. Short-course moxifloxacin therapy for treat-ment of acute bacterial exacerbations of chronic bronchi-tis. Resp Med 2000;94:18-27.
  • 51. Wilson R., Kubin R., Ballin I., et al. Five day moxiflo-xacin therapy compared with 7 day clarithromycin thera-py for the treatment of acute exacerbations of chronicbronchitis. J Antimicrob Chemother 1999;44: 501-13.
  • 52. Petipretz P., Arvis P., Marel M., et al. Oral moxifloxacinversus high-dosage amoxycillin in the treatment of mild-to-moderate, community-acquired, suspected pneumo-coccal pneumonia in adults. Chest 2001;119:185-95.
  • 53. Burke T., Villanueva C., Mariano H. Jr., et al. Compa-rison of moxifloxacin and cefuroxime axetil in the treat-ment of acute maxillary sinusitis. Clin Ther 1999;21:1664-77.
  • 54. Mandell L., Choudhri S.H., Kubin R. Safety assessmentof sequential IV/PO moxifloxacin in the treatment ofpatients with community-acquired pneumonia (CAP).11th ECCMID♦, Istanbul, Turkey, 1–4 April, 2001.p. 167-8.
  • 55. Iannini P.B., Kubin R., Reiter C. Over 10 million patientuses: An update on safety profile of oral moxifloxacin.42nd ICCAC†; 2002 Sep 27–30; San Diego, USA. p. 346.
  • 56. Parish L., Heyd A., Haverstock D., Church D. Efficacyand safety of moxifloxacin versus cephalexin in the treatment of mild to moderate acute uncomplicated skin andskin structure infections. J Antimicrob Chemother1999;44 (Suppl A):137.
  • 57. Leal del Rosal P., Martinez R., Fabian G., et al. Efficacyand safety of moxifloxacin vs cephalexin in the treatmentof mild to moderate uncomplicated skin and soft tissueinfections (uSSSI). J Antimicrob Chemother 1999;44(Suppl A):148.
  • 58. Leal del Rosal P., Fabian G., Vick-Fragoso R. Efficacyand safety of moxifloxacin vs cephalexin (with or withoutmetronidazole) in the treatment of mild to moderateuncomplicated skin and skin structures infections(uSSSI). 39th ICAAC†; 1999 Sep 26–29; San Francisco,USA. p. 716.
  • 59. Heystek M., Tellarini M., Schmitz H., Krasemann C. Effi-cacy and safety of moxifloxacin vs ciprofloxacin plusdoxycycline plus metronidazole for the treatment ofuncomplicated pelvic inflammatory disease (PID). JAntimicrob Chemother 1999;44 (Suppl A):143.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared